Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 2
2011 1
2014 2
2015 1
2016 1
2017 1
2018 4
2019 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Desjardins A, et al. N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26. N Engl J Med. 2018. PMID: 29943666 Free PMC article. Clinical Trial.
CONCLUSIONS: Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential. The survival rate among patients who received PVSRIPO immunotherapy was higher at 24 and 36 months than the rate …
CONCLUSIONS: Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neuro …
The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.
Denniston E, Crewdson H, Rucinsky N, Stegman A, Remenar D, Moio K, Clark B, Higginbotham A, Keffer R, Brammer S, Horzempa J. Denniston E, et al. Am J Virol. 2016;5(1):1-7. doi: 10.3844/ajvsp.2016.1.7. Epub 2016 Mar 3. Am J Virol. 2016. PMID: 28203321 Free PMC article.
Although viruses are the cause of numerous infectious diseases, these acellular entities have been harnessed over the years to benefit mankind. Recently, a recombinant Poliovirus-Rhinovirus Chimera (PVSRIPO) has shown promise for the treatment of glioblastoma in cli …
Although viruses are the cause of numerous infectious diseases, these acellular entities have been harnessed over the years to benefit manki …
Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
Brown MC, Gromeier M. Brown MC, et al. Curr Opin Virol. 2015 Aug;13:81-5. doi: 10.1016/j.coviro.2015.05.007. Epub 2015 Jun 12. Curr Opin Virol. 2015. PMID: 26083317 Free PMC article. Review.
An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targeted inflammatory cancer cell killing; a principle that is showing promise in clinical trials for recurrent glioblastoma (GBM). The two deci …
An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targeted in …
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
Stepanenko AA, Chekhonin VP. Stepanenko AA, et al. Cancers (Basel). 2018 Dec 5;10(12):492. doi: 10.3390/cancers10120492. Cancers (Basel). 2018. PMID: 30563098 Free PMC article. Review.
According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18-20 months for adult patients with newly diagnosed glioblastoma. These data explain a failure of positive non-controlled phase II trials to predict positive phase III tri …
According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18-20 months for adult patients with ne …
Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.
Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE. Chandramohan V, et al. Arch Pathol Lab Med. 2017 Dec;141(12):1697-1704. doi: 10.5858/arpa.2016-0580-OA. Epub 2017 Aug 22. Arch Pathol Lab Med. 2017. PMID: 28829151 Free PMC article.
To characterize the expression of CD155 in human glioblastoma cells as well as to evaluate the influence of CD155 expression levels on tumor cell susceptibility to PVSRIPO infection and killing. ...RESULTS: - We succeeded in developing a reliable assay to specifical …
To characterize the expression of CD155 in human glioblastoma cells as well as to evaluate the influence of CD155 expression levels o …
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE 2nd, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Lipp ES, Nair SK, Khasraw M, Peters KB, Randazzo D, Sampson JH, McLendon RE, Bigner DD, Ashley DM. Gromeier M, et al. Nat Commun. 2021 Jan 13;12(1):352. doi: 10.1038/s41467-020-20469-6. Nat Commun. 2021. PMID: 33441554 Free PMC article.
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy interv …
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here …
Recombinant Poliovirus for Cancer Immunotherapy.
Gromeier M, Nair SK. Gromeier M, et al. Annu Rev Med. 2018 Jan 29;69:289-299. doi: 10.1146/annurev-med-050715-104655. Annu Rev Med. 2018. PMID: 29414253 Free PMC article. Review.
In this review, we explain the mechanisms of recombinant nonpathogenic poliovirus, PVSRIPO, which is currently in phase I clinical trials against recurrent glioblastoma. ...
In this review, we explain the mechanisms of recombinant nonpathogenic poliovirus, PVSRIPO, which is currently in phase I clinical tr …
MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus.
Goetz C, Everson RG, Zhang LC, Gromeier M. Goetz C, et al. Mol Ther. 2010 Nov;18(11):1937-46. doi: 10.1038/mt.2010.145. Epub 2010 Jul 20. Mol Ther. 2010. PMID: 20648000 Free PMC article.
We report here that growth and cytotoxicity of the prototype oncolytic poliovirus (PV), PVSRIPO, in glioblastoma multiforme (GBM) is promoted by mitogen-activated protein kinases (MAPKs) converging on the MAPK signal-integrating kinase 1 (Mnk1) and its primary subst …
We report here that growth and cytotoxicity of the prototype oncolytic poliovirus (PV), PVSRIPO, in glioblastoma multiforme (G …
Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
Goetz C, Gromeier M. Goetz C, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):197-203. doi: 10.1016/j.cytogfr.2010.02.005. Epub 2010 Mar 17. Cytokine Growth Factor Rev. 2010. PMID: 20299272 Free PMC article. Review.
PVS-RIPO presents a novel approach to the treatment of patients with glioblastoma multiforme, based on conditions favoring an unconventional viral translation initiation mechanism in cancerous cells. ...
PVS-RIPO presents a novel approach to the treatment of patients with glioblastoma multiforme, based on conditions favoring an unconve …
Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW, Brown MC, Sacco MT, Gromeier M. Walton RW, et al. J Virol. 2018 Sep 12;92(19):e00879-18. doi: 10.1128/JVI.00879-18. Print 2018 Oct 1. J Virol. 2018. PMID: 29997212 Free PMC article.
We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated type 1 (Sabin) poliovirus vaccine carrying a heterologous internal ribosomal entry site (IRES) of human rhinovirus type 2 (HRV2). Intratumora …
We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated t …
17 results